Basilea PharmaceuticaXSWX:BSLN -0.57%62 Gross Margin % is 88.25% as of Dec. 2025, which is 6% above its 10-year median of 83.55. GuruFocus rates XSWX:BSLN with a GF Score™ of 62/100 and a GF Value™ of CHF57.38 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 735 Biotechnology companies, Basilea Pharmaceutica ranks better than 75.51% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Basilea Pharmaceutica had a gross margin of 88.25% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Basilea Pharmaceutica Gross Margin % Related Terms
Basilea Pharmaceutica Gross Margin % Historical Data
* Premium members only.
The historical data trend for Basilea Pharmaceutica's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BSLN vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Basilea Pharmaceutica's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basilea Pharmaceutica Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Basilea Pharmaceutica's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Basilea Pharmaceutica (XSWX:BSLN) has a Gross Margin % of 88.25% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Basilea Pharmaceutica and its competitors. This is near median its historical median of 83.55. Over the past decade, Basilea Pharmaceutica's Gross Margin % has ranged from 81.15 to 91.90. According to the industry distribution chart, Basilea Pharmaceutica ranks #180 out of 735 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Basilea Pharmaceutica's Gross Margin % too high?
Basilea Pharmaceutica's current Gross Margin % of 88.25% is near median its 10-year median of 83.55. Over the past 10 years, this metric has ranged from a low of 81.15 to a high of 91.90. The Biotechnology industry median Gross Margin % is 60.90. Basilea Pharmaceutica's value of 88.25% is 44.9% above this industry median. Based on the distribution chart, Basilea Pharmaceutica ranks #180 out of 735 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Basilea Pharmaceutica has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Basilea Pharmaceutica ranks #180 out of 735 companies for Gross Margin %. This places Basilea Pharmaceutica in the top 25% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.90. Basilea Pharmaceutica's value of 88.25% is 44.9% above this benchmark. Historically, Basilea Pharmaceutica's own Gross Margin % has ranged from 81.15 to 91.90 over the past decade. While the company's 10-year median is 83.55 vs. the industry median of 60.90, Basilea Pharmaceutica has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Basilea Pharmaceutica's current Gross Margin % of 88.25% is 44.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Basilea Pharmaceutica and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Basilea Pharmaceutica's current Gross Margin % is 88.25%, which is near median its own 10-year median of 83.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF57.38, compared to a current price of CHF51.90 — trading 9.6% below its estimated fair value. The current Gross Margin % is 88.25%, which is near median its 10-year median of 83.55 and 44.9% above the Biotechnology industry median of 60.90. Basilea Pharmaceutica's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Gross Margin % is 88.25% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?
Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued.
The current stock price of CHF51.90 is trading 9.6% below its estimated GF Value™ of CHF57.38.
GuruFocus considers Basilea Pharmaceutica to be Modestly Undervalued.
Key valuation signals for XSWX:BSLN:
Gross Margin %: 88.25% (near median its 10-year median of 83.55)
GF Value™: CHF57.38 vs. price of CHF51.90 (9.6% below fair value)
Industry Position: 44.9% above the Biotechnology median (#180 of 735)
No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
62GF Score
Get the complete analysis for XSWX:BSLN
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BSLN has been successfully added to your 
